ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

ÈÑÉï¸ÎÄÚµ¨Ö­ÓÙ»ýÖ¢»¼Õß´ÆÔм¤ËØˮƽ¼°ÃâÒß¹¦Äܵı仯_ҩѧרҵ±ÏÒµÂÛÎÄ

·¢²¼Ê±¼ä£º2014-11-18 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
ÈÑÉï¸ÎÄÚµ¨Ö­ÓÙ»ýÖ¢»¼Õß´ÆÔм¤ËØˮƽ¼°ÃâÒß¹¦Äܵı仯_ҩѧרҵ±ÏÒµÂÛÎÄ ¡¾ÕªÒª¡¿¡¡Ä¿µÄ¡¡Ì½ÌÖ´ÆÔм¤ËØˮƽ¼°ÃâÒß¹¦Äܱ仯ÓëÈÑÉï¸ÎÄÚµ¨Ö­ÓÙ»ýÖ¢£¨ICP£©µÄ¹Øϵ¡£·½·¨¡¡²ÉÓ÷ÅÉäÃâÒß·¨¡¢µ¥ÏòÃâÒßÀ©É¢·¨¡¢¼îÐÔÁ×Ëáø¼°¿¹¼îÐÔÁ×Ëáø·¨£¨APAAP£©¼ì²âICPÔи¾50Àý(ICP×é)¼°Õý³£ÈÑÉ︾Ů50Àý(¶ÔÕÕ×飩´ÆÔм¤ËØˮƽµÄ±ä»¯¡¢ÌåÒºÃâÒߺÍϸ°ûÃâÒß¹¦ÄܵÄˮƽ¡£¡¡½á¹û¡¡ICP×é´Æ¼¤ËØˮƽ(25.89¡À6.85 ¦Ìg/L)½Ï¶ÔÕÕ×é(16.92¡À4.98 ¦Ìg/L)Ã÷ÏÔÉý¸ß, (P£¼0.01)£¬Ôм¤ËØˮƽ²îÒìÎÞÏÔÖøÐÔ(P£¾0.05)£»ICP×éϸ°û¶¾ÐÔ-ÒÖÖÆÐÔTϸ°û£¨CD8+£©Ë®Æ½£¨19.06¡À1.93%)½Ï¶ÔÕÕ×é(26.43¡À2.89%)½µµÍ(P£¼0.05£©£¬¸¨ÖúÐÔ-ÓÕµ¼ÐÔTϸ°û£¨CD4+£©ÓëCD8+±ÈÖµ(2.23¡À0.38)½Ï¶ÔÕÕ×é(1.73¡À0.23)Éý¸ß(P£¼0.05)£»´Æ¼¤ËØˮƽÓëCD8+³Ê¸ºÏà¹Ø£¬ÓëCD4+/CD8+±ÈÖµ³ÊÕýÏà¹Ø¡£¡¡½áÂÛ¡¡ICP»¼ÕߴƼ¤ËØˮƽÔö¸ß£¬´Æ¼¤ËØͨ¹ýCD8+ÉϵĴƼ¤ËØÊÜÌå¶ø·¢»Ó×÷Ó㬵¼ÖÂÃâÒß¹¦Äܵĸı䣬¶øÒýÆðICPµÄ·¢Éú¡£   ¡¾Abstract¡¿¡¡Objective¡¡To explore the effects of estrogen, progesterone and the function of immune system on intrahepatic cholestasis of pregnancy (ICP).Methods¡¡Fifty women with ICP and fifty normal pregnant women were enrolled in the study. The levels of their serum estradiol (E2) and progesterone (P) were measured and cellular immunity and humoral immunity were determined. Radioimmunoassay was used to detect the levels of E2 and P, and APAAP was used to detect cellular immunity.Results¡¡(1)The level of estrodiol was significantly increased in ICP group than those of normal control group (25.89¡À6.85 ¦Ìg/L, 16.92¡À4.98 ¦Ìg/L, P£¼0.01).  (2)The level of CD8+ was decreased (19.06¡À1.93%, 26.43¡À2.89%)and the ratio of CD4+/ CD8+ was increased significantly in ICP group than those of control group (2.23 ¡À0.38, 1.73 ¡À0.23, P£¼0.05). (3)There were negative correlation between E2 and CD8+, and positive correlation between E2 and the ratio of CD4+/ CD8+.Conclusion¡¡These results suggest that the high level of E2 of ICP patients may result in functional disorder of immune system by the means of estrogen receptor on CD8+. This may be a factor of ICP development. ¡¾Key words¡¿¡¡Cholestasis,intrahepatic ¡¡¡¡Pregnancy ¡¡¡¡Estrogens¡¡¡¡Progesterone ¡¡¡¡ Immunity, cellular ÈÑÉï¸ÎÄÚµ¨Ö­ÓÙ»ýÖ¢(intrahepatic cholestasis of pregnancy,ICP)ÊÇÒ»ÖÖÈÑÉïºóÆÚÒÔƤ·ôðþÑ÷¡¢µ¨Ö­ÓÙ»ýºÍ»ÆðãΪÌØÕ÷µÄ¼²²¡¡£ICP»¼ÕßÔ¤ºóÁ¼ºÃ£¬µ«Ì¥¶ù¿É·¢ÉúÔç²ú¡¢¹¬ÄÚ¾½ÆÈ¡¢Ì¥ËÀ¹¬Äڵȡ£¹ØÓÚICP·¢²¡Ô­Òò£¬´æÔÚÐí¶àѧ˵£ºÈç´Æ¼¤ËØÓÕµ¼µÄICPѧ˵¡¢¼Ò×åÒÅ´«Ñ§Ëµ¡¢ÍâÔ´ÐÔÒòËØѧ˵µÈ¡£Ëæ×ÅÉñ¾­ÄÚ·ÖÃÚÃâÒßѧµÄ·¢Õ¹£¬¹úÍâһЩѧÕ߶ÔÉñ¾­ÄÚ·ÖÃÚÃâÒßµ÷½ÚÔÚICP·¢Éú¹ý³ÌÖеÄ×÷ÓÃÔ½À´Ô½ÖØÊÓ¡£ÎÒÃǶԴơ¢Ôм¤ËØˮƽ¼°ÃâÒß¹¦ÄܸıäÓëÈÑÉï¸ÎÄÚµ¨Ö­ÓÙ»ýÖ¢µÄÏà¹ØÐÔ½øÐÐÁËÑо¿¡£ÏÖ±¨µÀÈçÏ¡£ ×ÊÁÏÓë·½·¨ Ò»¡¢Ñо¿¶ÔÏó Ñ¡Ôñ1996Äê6Ô¡«1997Äê1Ô»ª¿Æ´óѧ¸½ÊôµÚ¶þÒ½ÔºÃÅÕPסԺÕßÖУ¬ICP»¼Õß50Àý(ICP×é)¼°Õý³£ÈÑÉ︾Ů50Àý(¶ÔÕÕ×é)£¬Á½×é²ú¸¾ÄêÁä·Ö±ðΪ27.3¡À2.4Ë꣬27.03¡À2.9Ë꣬ÔÐÖÜ·Ö±ðΪ36.9¡À1.6ÖÜ£¬36.50¡À2.5ÖÜ£¬¾ùΪµ¥Ì¥³õ²ú¸¾¡£ICP×éÄÉÈë±ê×¼£º(1)ÈÑÉïÇ°ÎÞ¸ÎÔà¡¢µ¨µÀµÈ¼±ÂýÐÔ¼²²¡Ê·£»(2)ÈÑÉïÆÚ³öÏÖÇû¸É¼°ËÄ֫Ƥ·ôðþÑ÷£»(3)ʵÑéÊÒ¼ì²é£¬ÑªÇå×ܵ¨ËáÉý¸ß£¬×ª°±Ã¸ÓÐÇá¶È»òÖжÈÉý¸ß£»×ܵ¨ºìËؼ°Ö±½Óµ¨ºìËØÕý³£»òÉý¸ß£»(4)ÎÞƤ·ô²¡Õߣ»(5)·ÖÃäºóÉÏÊöÖ¢×´¼°ÊµÑéÊÒ¼ì²é¾ùÖð½¥»Ö¸´Õý³£¡£ ¶þ¡¢·½·¨ 1. ´Æ¡¢Ôм¤ËØˮƽµÄ¼ì²â£º²ÉÓ÷ÅÉäÃâÒß·¨£¬ºÐ¹º×ÔÎÀÉú²¿ÉϺ£ÉúÎïÖÆÆ·Ñо¿Ëù¡£ 2. TÁÜ°Íϸ°ûÑÇȺ¼ì²â£º²ÉÓüîÐÔÁ×Ëáø¼°¿¹¼îÐÔÁ×Ëáø·¨(APAAP)·¨£¬Ò©ºÐ¹º×Ô¾üÊ¿ÆѧԺÉúÎïÖƼÁ·¢Õ¹ÖÐÐÄ¡£ 3. ÃâÒßÇòµ°°×µÄ¼ì²â£º²ÉÓõ¥ÏòÃâÒßÀ©É¢·¨,Ò©ºÐ¹º×ÔÎÀÉú²¿ÉϺ£ÉúÎïÖÆÆ·Ñо¿Ëù¡£ Èý¡¢Ñ§´¦Àí Á½×é¼ä¼ÆÁ¿×ÊÁϱȽÏÓÃt£¬Á½±äÁ¿¼äµÄÏà¹Ø¹ØϵÓÃÖ±ÏßÏà¹Ø·ÖÎö·¨¡£ ½á¹û Ò»¡¢¼¤ËØˮƽµÄ±ä»¯ ´Æ¡¢Ôм¤ËØˮƽ¾ùËæÔÐÖÜÔö¼Ó¶øÉý¸ß¡£Á½×é½á¹û¾ùÏÔʾ£¬ICP×é´Æ¼¤ËØˮƽ¸ßÓÚ¶ÔÕÕ×é(P£¼0.01)£¬¶øÔм¤ËØˮƽÔÚÁ½×é¼äµÄ²îÒìÎÞÏÔÖøÐÔ(P£¾0.05)£¬¼û±í1¡£ ±í1¡¡Á½×é´Æ¡¢Ôм¤Ëزⶨ½á¹û(¦Ìg/L£¬) ×é±ð ÀýÊý ´Æ¼¤ËØ Ôм¤ËØ  ¶ÔÕÕ×é 50 16.92¡À4.98 225.71¡À84.51  ICP×é 50 25.89¡À6.85 253.77¡À67.50  ¶þ¡¢ÌåÒºÃâÒߵı仯 ICP×éµÄÃâÒßÇòµ°°×IgGˮƽµÍÓÚ¶ÔÕÕ×é(P£¼0.01)¶øÃâÒßÇòµ°°×IgM¡¢IgA¼°²¹ÌåC3¡¢C4ˮƽÓë¶ÔÕÕ×éÏà±È£¬²îÒìÎÞÏÔÖøÐÔ£¬¼û±í2¡£ Èý¡¢Ï¸°ûÃâÒßÖ¸±êµÄ±ä»¯ ICP×鸨ÖúÐÔ-ÓÕµ¼ÐÔTϸ°û(CD4+)¡¢³ÉÊìTϸ°û£¨CD3+£©Óë¶ÔÕÕ×éÏà±È£¬²îÒìÎÞÏÔÖøÐÔ(P£¾0.05£¬P£¾0.2)¡£Ï¸°û¶¾ÐÔ-ÒÖÖÆÐÔTϸ°û(CD8+)ˮƽÔò½Ï¶ÔÕÕ×éµÍ(P£¼0.05)£¬CD4+/ CD8+±ÈÖµÔö¸ß(P£¼0.05)£¬¼û±í3¡£ ËÄ¡¢´Æ¼¤ËØˮƽÓëÃâÒßÖ¸±êµÄÏà¹ØÐÔ·ÖÎö ´Æ¼¤ËØˮƽÓëCD8+³Ê¸ºÏà¹Ø£¨r£½-0.581£¬P£¼0.05£©ÓëCD4+/CD8+³ÊÕýÏà¹Ø(r=0.623£¬P£¼0.05),¶øÓëÆäÓàÖ¸±êδ¼ûÓÐÏà¹ØÐÔ¡£ ÌÖÂÛ Ò»¡¢ÃâÒß¹¦ÄܵĸıäÓëICP·¢²¡µÄ¹Øϵ 1£®ÌåÒºÃâÒߵı仯£ºÈÑÉïÆÚËæ×ÅÅßÌ¥µÄÉú³¤·¢Óý£¬Ì¥¶ùµÄÃâÒßϵͳÏàÓ¦½¨Á¢¡£20ÖܵÄÅßÌ¥¼´¿ÉºÏ³ÉÃâÒßÇòµ°°×¡£ËùÒÔ£¬Ì¥¶ù¶Ôͨ¹ýÌ¥ÅÌ͸ÈëµÄĸÌ忹ԭÄܹ»²úÉúÃâÒß·´Ó¦¡£È»¶ø£¬Õý³£ÈÑÉïʱ²¢Ã»ÓÐÅųⷴӦ·¢Éú¡£¾¿ÆäÔ­Òò£¬³ýÃâÒßÄÍÊÜÍ⣬»¹´æÔÚ×ÅÆäËüÃâÒßµ÷½Ú×÷Óã¬ÆäÖÐÖ®Ò»¼´Îª·â±Õ¿¹Ìå¡£´óÁ¿µÄÑо¿Ö¤Êµ£¬·â±Õ¿¹ÌåΪIgG¼°ÆäÑÇÀ࿹Ì壬ÕâÖÖ¿¹Ìå¾ßÓб£»¤×÷Óã¬ÄÜÓë×ÌÑø²ãϸ°ûµÄ±íÃ濹ԭ½áºÏ£¬·â±ÕÆ俹ԭ¾ö¶¨´ØʹÆä²»ÄÜÓëĸÌåϸ°û¶¾ÐÔTϸ°û½áºÏ£¬²¢ÃâÊÜĸÌåÖÂÃôÁÜ°Íϸ°ûµÄ¹¥»÷¡£ÔÚÁÙ´²ÉÏÒÑ֤ʵ£¬·´¸´×ÔÈ»Á÷²úÓë·â±Õ¿¹Ìåȱ·¦ÓйأÛ1£¬2£Ý¡£±¾Ñо¿ÏÔʾ£¬ICP»¼ÕßµÄIgG ˮƽ½ÏÕý³£ÈÑÉïÃ÷ÏÔ¼õÉÙ£¬ÕâÖÖ·â±Õ¿¹ÌåµÄ¼õÉÙµ¼Ö±£»¤×÷ÓüõÈõ£¬¶ø·¢ÉúÃâÒß·´Ó¦¡£ 2£®Ï¸°ûÃâÒß¹¦Äܵĸı䣺CD4+µÄÖ÷Òª×÷ÓÃÊÇ´Ù½øBϸ°û¡¢Tϸ°ûºÍÆäËüÃâÒßϸ°ûµÄÔöÖ³Óë·Ö»¯£¬Ð­µ÷ÃâÒßϸ°û¼äµÄÏ໥×÷Óá£CD8+ÖеÄÒÖÖÆÐÔTϸ°û£¨Ts£©µÄÖ÷Òª×÷ÓÃÊÇÒÖÖÆBϸ°û²úÉú¿¹ÌåÃâÒßÓ¦ ±í2¡¡Á½×éÌåÒºÃâÒßÖ¸±ê²â¶¨½á¹û(g/L£¬) ×é±ð ÀýÊý IgG IgM IgA C3 C4  ICP×é 50 5.89¡À0.74 1.02¡À0.42 1.04¡À0.57 1.09¡À0.27 0.56¡À0.16  ¶ÔÕÕ×é 50 7.89¡À1.85 1.15¡À0.42 1.017¡À0.57 1.02¡À0.29 0.62¡À0.19  PÖµ ¡¡ £¼0.01 £¾0.05 £¾0.2 £¾0.5 £¾0.1  ±í3¡¡Á½×éϸ°ûÃâÒßÖ¸±ê²â¶¨½á¹û(%£¬) ×é±ð ÀýÊý CD3+ CD4+ CD8+ CD4+/CD8+   ICP×é 50 69.9¡À7.24 43.37¡À4.38 19.06¡À1.93 2.23¡À0.38  ¶ÔÕÕ×é 50 73.67¡À6.81 45.4¡À4.83 26.43¡À2.89 1.73¡À0.23  PÖµ ¡¡ £¾0.05 £¾0.2 £¼0.05 £¼0.05  ´ð£¬ÔÚ»úÌåµÄÃâÒßµ÷½ÚÖУ¬ÆðÖ÷Òª×÷Óá£CD4+ÓëCD8+ϸ°û¼äͨ¹ýÏ໥Эµ÷¡¢Ï໥ÖÆÔ¼£¬´Ó¶øµ÷¿Ø×Å»úÌåµÄÃâÒß״̬¡£Òò´Ë£¬CD4+/ CD8+±ÈÖµµÄ±ä»¯ÔÚÃâÒßµ÷¿ØÖз¢»Óןü¼ÓÖ÷ÒªµÄ×÷Óᣱ¾ÊµÑé·¢ÏÖICP»¼ÕßCD8+ˮƽÃ÷ÏÔϽµ£¬CD4+/ CD8+±ÈÖµÔö¸ß£¬Õâ¿ÉÄÜÓ뻼Õßĸ-Ì¥ÃâÒßƽºâʧµ÷£¬±£»¤·´Ó¦¼õÈõ£¬ÅųⷴӦÔöÇ¿Óйء£ ¶þ¡¢´Æ¼¤ËØ-ÃâÒßµ÷½ÚÓëICP·¢²¡µÄÏà¹ØÐÔ ±¾Ñо¿½á¹ûÏÔʾÁËICP»¼ÕßµÄÌåÒºÃâÒßÓëϸ°ûÃâÒß³öÏÖ·ÖÀëµÄ״̬£¬¼´ICP»¼ÕßCD8+ÊýÄ¿Ã÷ÏÔϽµ£¬ÒÖÖÆ¿¹ÌåÉú³ÉµÄ×÷ÓüõÈõ£¬¿¹Ìå·ÖÃÚÓ¦Ôö¼Ó£¬µ«ICP»¼ÕßIgGˮƽ²»µ«Ã»ÓÐÉý¸ß·´¶øÃ÷ÏÔϽµ£¬Õâ¿ÉÄÜÊÇÒòΪ´æÔÚ×ŴƼ¤ËصÄÓ°Ïì¡£´óÁ¿Ñо¿ÒѾ­Ö¤Êµ´Æ¼¤ËضÔBÁÜ°Íϸ°û½øÐÐ
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö